GENOMED4ALL: Improving MDS Classification and Prognosis by AI

Summary

Myelodysplastic syndromes (MDS) typically occur in elderly people. Current disese classifcation system and prognostic scores (International Prognostic Scoring System, IPSS) present limitations and in most cases fail to capture reliable prognostic information at individual level. Study of MDS has been rapidly transformed by genome characterization and there is increasing evidence that mutation screening may add significant information to currently available prognostic scores. The project will aim to develop artificial intelligence (AI)-based solutions to improve MDS classification and prognostication, through the implementation of a personalized medicine approach. In close collaboration with the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541), GENOMED4ALL involves multiple clinical partners from the network, while leveraging on healthcare information and repositories that will be gathered incorporating interoperability standards as promoted by ERN-EuroBloodNet central registry, the European Rare Blood Disorders Platform (ENROL, GA 947670).

Conditions

• Myelodysplastic Syndromes

Sponsors & Collaborators

• Istituto Clinico Humanitas

  lead OTHER

Principal Investigators

• Federico Alvarez · UNIVERSIDAD POLITECNICA DE MADRID SPAIN

• Lucia Comnes · DATAWIZARD SRL ITALY

• Mar Manu Pereira · FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA SPAIN

• Pierre Fenaux · ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FRANCE

• Torsten Haferlach · MLL MUNCHNER LEUKAMIELABOR GMBH GERMANY

• Maria Diez Campelo · Instituto de investigacion biomedica de Salamanca, IBSAL SPAIN

• Uwe Platzbecker · UNIVERSITAET LEIPZIG GERMANY

• Gastone Castellani · ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA ITALY

• Andres Krogh · KOBENHAVNS UNIVERSITET DENMARK

• Babita Singh · FUNDACIO CENTRE DE REGULACIO GENOMICA SPAIN

• Piero Fariselli · UNIVERSITA DEGLI STUDI DI TORINO ITALY

• Kostantinos Marias · IDRYMA TECHNOLOGIAS KAI EREVNAS GREECE

• Mar Mañu Pereira · European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet)

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-03-15

Primary Completion

2022-12-15

Completion

2024-12-31

Countries

• Italy

Study Locations